Journey Medical Corp Cash Flow Conversion Efficiency
Journey Medical Corp cash flow conversion efficiency. Based on the latest financial reports, Journey Medical Corp (DERM) has a cash flow conversion efficiency ratio of -0.200x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.36 Million) by net assets ($31.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Journey Medical Corp (2014–2025)
Cash flow conversion efficiency of Journey Medical Corp from 2014 to 2025. This chart illustrates how Journey Medical Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View DERM live share price for real-time trading data and today's change.
Journey Medical Corp Cash Flow Conversion Ratio Explained
Journey Medical Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Journey Medical Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Journey Medical Corp ranked by their cash flow conversion efficiency. Also see market cap of Journey Medical Corp for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
STARPHARMA HLDG.SP.ADR/10
F:PQ6A
|
N/A |
|
Leaders Technology Investment Co. Ltd
KQ:019570
|
-0.238x |
|
Voss Veksel og Landmandsbank ASA
OL:VVL
|
0.227x |
|
Team Precision Public Company Limited
BK:TEAM
|
-0.034x |
|
WW Holding Inc
TW:8442
|
0.012x |
|
Pelita Samudera Shipping Tbk PT
JK:PSSI
|
0.033x |
|
UNICOMMERCE ESOLUTIONS LIMITED
NSE:UNIECOM
|
0.154x |
|
Polytec Holding AG
VI:PYT
|
0.182x |
Annual Cash Flow Conversion Efficiency for Journey Medical Corp (2014–2025)
The table below shows the annual cash flow conversion efficiency of Journey Medical Corp from 2014 to 2025. Review DERM free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $31.85 Million | $-12.44 Million | -0.391x | +14.12% |
| 2024-12-31 | $20.07 Million | $-9.13 Million | -0.455x | -276.62% |
| 2023-12-31 | $20.35 Million | $5.24 Million | 0.257x | +132.31% |
| 2022-12-31 | $16.98 Million | $-13.53 Million | -0.797x | -1436.30% |
| 2021-12-31 | $42.04 Million | $-2.18 Million | -0.052x | -110.40% |
| 2020-12-31 | $10.29 Million | $5.13 Million | 0.499x | -84.78% |
| 2019-12-31 | $2.75 Million | $9.02 Million | 3.277x | -86.10% |
| 2018-12-31 | $-9.04 Million | $-213.10 Million | 23.575x | +3493.55% |
| 2017-12-31 | $149.65 Million | $-103.96 Million | -0.695x | -131.88% |
| 2016-12-31 | $247.37 Million | $-74.11 Million | -0.300x | -14.71% |
| 2015-12-31 | $185.47 Million | $-48.44 Million | -0.261x | -27.73% |
| 2014-12-31 | $153.58 Million | $-31.40 Million | -0.204x | -- |
About Journey Medical Corp
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat sev… Read more